CL2004001050A1 - Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul - Google Patents

Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul

Info

Publication number: CL2004001050A1
Authority: CL; Chile
Prior art keywords: asthma; treatment; trifluoroetil; ciclopropil; bifenil
Prior art date: 2002-11-22

Application number

CL200401050A

Other languages

English (en)

Inventor

Daniel Dube

Michel Gallant

Patrick Lacombe

Renee Aspiotis

Laurence Dube

Dwight Macdonald

Original Assignee

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-22

Filing date

2004-05-14

Publication date

2005-03-28

2004-05-14 Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd

2005-03-28 Publication of CL2004001050A1 publication Critical patent/CL2004001050A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Dermatology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL200401050A 2002-11-22 2004-05-14 Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul CL2004001050A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42861102P	2002-11-22	2002-11-22

Publications (1)

Publication Number	Publication Date
CL2004001050A1 true CL2004001050A1 (es)	2005-03-28

Family

ID=32393431

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200401050A CL2004001050A1 (es)	2002-11-22	2004-05-14	Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul

Country Status (23)

Country	Link
US (2)	US7342024B2 (es)
EP (1)	EP1565464B1 (es)
JP (1)	JP4499571B2 (es)
KR (1)	KR20050085112A (es)
CN (1)	CN100475813C (es)
AT (1)	ATE402175T1 (es)
AU (1)	AU2003283167B2 (es)
BR (1)	BR0316458A (es)
CA (1)	CA2506648C (es)
CL (1)	CL2004001050A1 (es)
DE (1)	DE60322417D1 (es)
EC (1)	ECSP055809A (es)
HR (1)	HRP20050451A2 (es)
IS (1)	IS7839A (es)
MA (1)	MA27566A1 (es)
MX (1)	MXPA05005413A (es)
NO (1)	NO20053046L (es)
NZ (1)	NZ539812A (es)
PL (1)	PL377237A1 (es)
RU (1)	RU2312865C2 (es)
UA (1)	UA82208C2 (es)
WO (1)	WO2004048374A1 (es)
ZA (1)	ZA200503586B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
JO2311B1 (en) *	2001-08-29	2005-09-12	ميرك فروست كندا ليمتد	Alkyl inhibitors Ariel phosphodiesterase-4
IS7839A (is) *	2002-11-22	2004-05-23	Merck Frosst Canada Ltd.	4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
AR057555A1 (es) *	2005-10-27	2007-12-05	Merck Frosst Canada Ltd	Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
WO2007050576A2 (en) *	2005-10-27	2007-05-03	Merck & Co., Inc.	A method of preparing a 4-oxo-1- (3 substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3- carboxamide phosphodiesterase-4 inhibitor
CN102772411A (zh)	2006-07-05	2012-11-14	奈科明有限责任公司	用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
US10954231B2 (en)	2006-10-16	2021-03-23	Bionomics Limited	Anxiolytic compounds
CA2666219C (en)	2006-10-16	2017-02-07	Bionomics Limited	Novel anxiolytic compounds
MX2009009793A (es) *	2007-03-14	2009-10-16	Ranbaxy Lab Ltd	Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
KR20100014565A (ko) *	2007-04-11	2010-02-10	알콘 리서치, 리미티드	알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US8563566B2 (en) *	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
KR101605576B1 (ko)	2008-05-27	2016-03-22	아스트라제네카 아베	페녹시피리디닐아미드 유도체 및 ｐｄｅ４ 매개 질환 상태의 치료에서의 그의 용도
MX2012003693A (es) *	2009-10-01	2012-04-19	Alcon Res Ltd	Composiciones de olopatadine y usos de las mismas.
ES2662350T3 (es) *	2010-07-01	2018-04-06	Azevan Pharmaceuticals, Inc.	Procedimientos para el tratamiento del trastorno por estrés postraumático
CA2828780A1 (en)	2011-03-02	2012-09-07	Bionomics Limited	Novel small-molecules as therapeutics
WO2012151640A1 (en)	2011-05-12	2012-11-15	Bionomics Limited	Methods for preparing naphthyridines
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
ES2635067T3 (es) *	2012-06-15	2017-10-02	Bio-Pharm Solutions Co., Ltd.	Compuesto de sulfamato de fenilalquilo y composición de relajante muscular que comprende el mismo
CA2905242C (en)	2013-03-15	2016-11-29	Pfizer Inc.	Indole compounds that activate ampk
CN106316824B (zh) *	2016-08-18	2018-10-19	广州康瑞泰药业有限公司	一种合成2-氟环丙烷甲酸的新方法
IL267299B (en) *	2016-12-16	2022-09-01	Cstone Pharmaceuticals	Cdk4/6 inhibitor
MX2021007938A (es)	2018-12-28	2022-01-24	Regeneron Pharma	Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2808070A1 (de)	1978-02-24	1979-08-30	Bayer Ag	Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US5328908A (en)	1988-10-24	1994-07-12	Procter & Gamble Pharmaceuticals, Inc.	Antimicrobial quinolone thioureas
US5321029A (en) *	1988-11-14	1994-06-14	Beecham-Wuelfing Gmbh & Co.K.G.	Xanthines
KR970705562A (ko)	1994-08-29	1997-10-09	오노다 마사요시	신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
ES2211965T3 (es)	1995-08-02	2004-07-16	Darwin Discovery Limited	Quinolonas y su utilizacion terapeutica.
ES2200439T3 (es) *	1995-09-22	2004-03-01	Wakunaga Pharmaceutical Co., Ltd.	Intermedios para utilizar en la preparacion de nuevos derivados del acido piridonocarboxilico o sus sales.
EP0958297A1 (en)	1997-08-06	1999-11-24	Suntory Limited	1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
JPH11106385A (ja) *	1997-08-06	1999-04-20	Suntory Ltd	Ｉｖ型ホスホジエステラーゼ阻害作用を有する１−アリール−１，８−ナフチリジン−４−オン誘導体
US6306869B1 (en) *	1998-05-05	2001-10-23	Byk Gulden Lomberg Chemische Febrik Gmbh	N-oxides
AR029185A1 (es) *	1999-10-25	2003-06-18	Yamanouchi Pharma Co Ltd	Derivado de naftiridina
US6794447B1 (en) *	2000-07-28	2004-09-21	Taylor Made Golf Co., Inc.	Golf balls incorporating nanocomposite materials
JP4460221B2 (ja) *	2001-05-24	2010-05-12	メルクフロストカナダリミテツド	１−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
KR100824233B1 (ko) *	2001-10-10	2008-04-24	씨제이제일제당 (주)	사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1ｈ-나프탈렌 유도체
IS7839A (is) *	2002-11-22	2004-05-23	Merck Frosst Canada Ltd.	4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

2003
- 2003-05-09 IS IS7839A patent/IS7839A/is unknown
- 2003-11-19 AU AU2003283167A patent/AU2003283167B2/en not_active Ceased
- 2003-11-19 CA CA2506648A patent/CA2506648C/en not_active Expired - Fee Related
- 2003-11-19 HR HR20050451A patent/HRP20050451A2/hr not_active Application Discontinuation
- 2003-11-19 UA UAA200506089A patent/UA82208C2/uk unknown
- 2003-11-19 WO PCT/CA2003/001800 patent/WO2004048374A1/en not_active Ceased
- 2003-11-19 KR KR1020057009238A patent/KR20050085112A/ko not_active Ceased
- 2003-11-19 RU RU2005119644/04A patent/RU2312865C2/ru not_active IP Right Cessation
- 2003-11-19 EP EP03775029A patent/EP1565464B1/en not_active Expired - Lifetime
- 2003-11-19 PL PL377237A patent/PL377237A1/pl not_active Application Discontinuation
- 2003-11-19 MX MXPA05005413A patent/MXPA05005413A/es active IP Right Grant
- 2003-11-19 BR BR0316458-6A patent/BR0316458A/pt not_active IP Right Cessation
- 2003-11-19 US US10/534,582 patent/US7342024B2/en not_active Expired - Fee Related
- 2003-11-19 NZ NZ539812A patent/NZ539812A/en not_active IP Right Cessation
- 2003-11-19 CN CNB2003801089525A patent/CN100475813C/zh not_active Expired - Fee Related
- 2003-11-19 AT AT03775029T patent/ATE402175T1/de not_active IP Right Cessation
- 2003-11-19 JP JP2004554102A patent/JP4499571B2/ja not_active Expired - Fee Related
- 2003-11-19 DE DE60322417T patent/DE60322417D1/de not_active Expired - Lifetime
2004
- 2004-01-23 US US10/764,229 patent/US7238706B2/en not_active Expired - Fee Related
- 2004-05-14 CL CL200401050A patent/CL2004001050A1/es unknown
2005
- 2005-05-05 ZA ZA200503586A patent/ZA200503586B/en unknown
- 2005-05-20 EC EC2005005809A patent/ECSP055809A/es unknown
- 2005-06-16 MA MA28338A patent/MA27566A1/fr unknown
- 2005-06-21 NO NO20053046A patent/NO20053046L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US7342024B2 (en)	2008-03-11
EP1565464A1 (en)	2005-08-24
MXPA05005413A (es)	2005-08-03
RU2005119644A (ru)	2006-01-20
DE60322417D1 (en)	2008-09-04
AU2003283167B2 (en)	2009-01-08
US20060058316A1 (en)	2006-03-16
CN1738819A (zh)	2006-02-22
ECSP055809A (es)	2005-08-11
JP4499571B2 (ja)	2010-07-07
NO20053046D0 (no)	2005-06-21
WO2004048374A1 (en)	2004-06-10
MA27566A1 (fr)	2005-10-03
PL377237A1 (pl)	2006-01-23
NZ539812A (en)	2007-12-21
HRP20050451A2 (en)	2006-02-28
EP1565464B1 (en)	2008-07-23
UA82208C2 (en)	2008-03-25
CA2506648C (en)	2011-01-25
IS7839A (is)	2004-05-23
KR20050085112A (ko)	2005-08-29
BR0316458A (pt)	2005-10-11
ZA200503586B (en)	2006-07-26
ATE402175T1 (de)	2008-08-15
US7238706B2 (en)	2007-07-03
RU2312865C2 (ru)	2007-12-20
AU2003283167A1 (en)	2004-06-18
JP2006508989A (ja)	2006-03-16
CA2506648A1 (en)	2004-06-10
US20050107402A1 (en)	2005-05-19
CN100475813C (zh)	2009-04-08
NO20053046L (no)	2005-07-27

Publication	Publication Date	Title
CL2004001050A1 (es)	2005-03-28	Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
BR0212042A (pt)	2004-08-17	Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
GEP20053600B (en)	2005-08-10	3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
BR0315337A (pt)	2005-08-16	Composto, formulação farmacêutica, e, método para tratar câncer
UY27755A1 (es)	2003-11-28	Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
SE0202463D0 (sv)	2002-08-14	Novel compounds
GEP20053675B (en)	2005-11-25	Pyridazinone Aldose Reductase Inhibitors
ECSP055525A (es)	2005-03-10	Inhibidores de cinasas de tirosina
ECSP055701A (es)	2005-05-30	Nuevos derivados de pirimidinamida y el uso de los mismos
BR0210122A (pt)	2004-06-15	Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
GEP20094605B (en)	2009-02-10	Pyrazole derivatives, compositions containing such compounds and methods of use thereof
BR0309343A (pt)	2005-02-15	Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt)	2005-02-15	Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
IS2517B (is)	2009-06-15	Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ATE303384T1 (de)	2005-09-15	1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MY140630A (en)	2010-01-15	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2003250471A8 (en)	2004-02-25	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
SE0102055D0 (sv)	2001-06-08	New Compounds
TW200504029A (en)	2005-02-01	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0205812A (pt)	2005-05-03	Benzimidazois úteis no tratamento da disfunção sexual
BR0314844A (pt)	2005-08-09	Novo composto
BR0314843A (pt)	2005-08-09	Novo composto
DE60220055D1 (de)	2007-06-21	4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
MXPA05013050A (es)	2006-03-02	Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
SE0302570D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof